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Abstract
Introduction A diverse range of human diseases, including
allergy, asthma, autoimmune disease, cancer and chronic
neurologic diseases, notably multiple sclerosis and endoge-
nous depression, is becoming more prevalent in industrial-
ized countries. It has been postulated that environmental
factors associated with improved standards of hygiene play a
leading role in this process since the immune system seems
to need extrinsic challenges for its proper maturation.
The inner world An added dimension has now
emerged—the impact on disease of the inner world, princi-
pally the numerous endogenous retroviruses (HERVs)
within the human genome. Taking melanoma as an exam-
ple, we propose a framework for understanding how a com-
plex infectious and immunological background can induce
or inhibit expression of a HERV-related disease process.
The central role of a failure to induce or to maintain certain
populations of self-speciWc CD8+ T-cells mediating immune
surveillance, the expression of HERV-encoded peptides on
aVected cells and pathological mechanisms directly attrib-
utable to HERV proteins are discussed.
Conclusions The presented concepts explain events pre-
ceding the clinical manifestation of diseases by several
years and provide a rationale for the use of currently avail-
able vaccines to protect against certain HERV-induced
diseases, especially melanoma. Criteria for establishing the
causal role of HERVs in a given disease are proposed.
Keywords Melanoma · Hygiene hypothesis · HERV · 
Immune repair · Koch postulates
Introduction
The term Darwinian medicine has been applied to the study
of the interplay between inherited genetic characteristics
and the very rapid societal changes, notably those in the
industrialised nations, that have occurred over the last few
centuries (Rook 2009). Studies in this Weld have, in particu-
lar, focused on the increasing isolation of the human popu-
lation from many micro-organisms that millions of years of
evolution have led the immune system to ‘expect’ to
acquire as drivers of immunoregulatory pathways. The con-
siderable increase in the industrialised nations of a number
of conditions, including allergies, a wide range of autoim-
mune disorders and certain cancers has been attributed to
inadequate or inappropriate development of the immune
system and its regulatory pathways. These conditions are
all characterised by chronic inXammation (Rook 2007),
which, in contrast to acute inXammation, is a manifestation
of dysregulated, and potentially inappropriate immune
reactivity (Bottasso et al. 2009). As well as initiating cer-
tain cancers, the key relevance of chronic inXammation to
the subsequent development and maintenance of most if not
all cancers has been highlighted in recent years; indeed
such inXammation has been termed “the other half of the
tumour” (Mantovani et al. 2008).
Initially, the hygiene-related factor responsible for the
changing pattern of disease was thought to be a reduced
exposure to a range of previously common infectious
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diseases during childhood, but it now seems likely that the
relevant micro-organisms from which we are increasingly
isolated also include commensals and saprophytes, such as
actinomycetes, that are acquired by the oral route. Intestinal
helminth infestations, once universal and usually harmless,
may have protected against allergic disorders and, possibly,
some of the other conditions referred to above. The term
‘old friends’ has been applied to putative beneWcial micro-
bial populations (Rook 2007).
Another consequence of improving standards of hygiene
is that certain infections once almost universally acquired
in infancy are now acquired at a later age and the immune
response to such infections in older people may be quite
diVerent than in infants, sometimes with deleterious conse-
quences. The outcome of the nature and sequence of infec-
tions and other antigenic challenges during the lifetime of a
person has been linked with the ‘biography’ of the immune
system (Krone et al. 2009). To date, Darwinian medicine
has focused on external factors, notably the acquisition, or
lack of acquisition, of commensal and pathogenic micro-
organisms from the surrounding environment, but there is
another key emerging theme in this important Weld of
human medicine.
Human endogenous retroviruses
The complete sequencing of the human genome revealed
many surprises, not least of which is that almost half of the
genome is composed of, or derived from, virus-like ele-
ments. As our planet, with its abundant supply of water and
the eventual emergence of life on its surface, evolved as the
result of many catastrophic collisions with asteroids and
comets, so that which was ultimately to become the human
genome appears to have enlarged and evolved as a result of
numerous collisions with viral DNA (Kazazian 2004). The
term ‘virolution’ has been applied by Frank Ryan to this
key aspect of our overall evolution (Ryan 2009a), and the
subject has been summarised in a series of excellent
reviews by the same author (Ryan 2009b).
The components of the viral content of the human chro-
mosome that may well have had the most signiWcant impact
on evolution are the human endogenous retroviruses
(HERVs), which comprise around 8 percent of the chromo-
some and represent around 400,000 genetic loci. These
HERVs have been acquired over millions of years and
many diVerent families and sub-families have been
described (Bannert and Kurth 2004; Dolei and Perron
2009). The earlier the ‘hit’, the more fragmented is the
residual chromosomal DNA. Thus HERVs of the W series
are the oldest yet found, having been acquired by our pri-
mate ancestors around 40 million years ago. By contrast,
those of the K series were acquired between 3 and 6 million
years ago, at the time of the human-chimpanzee split, and
may indeed have played a key role in mediating this split
(Sverdlov 2000). Probably due to their relatively recent ori-
gin, those of the K series are the most complete and biolog-
ically active of the HERVs and are able to induce the
formation of replicating virus particles (Ryan 2009a),
though infectivity has not been demonstrated (Boller et al.
2008). These whole virus particles can, however, co-package
RNA from HERVs that are unable to directly induce such
particles (Ruprecht et al. 2008). Whether also exogenous
xenotropic retroviruses could become involved is far from
clear (Lo et al. 2010).
HERVs contain a small group of functional genes (env,
gag, and pol, similar to those in other retroviruses including
HIV) Xanked by regulatory genetic units termed long termi-
nal repeats (LTRs). Some functional HERV genes now
code for indispensible human proteins. Thus, for example,
the expression of the env regions of three HERVs—ERV-3,
HERV-W and HERV-FRD—is essential for the formation
of the placental syncytiotrophoblast and the HERV-FRD
component appears to be involved in the suppression of
immune reactivity that might otherwise reject the foetus
(Rote et al. 2004). Once established in the host DNA,
HERVs produce multiple copies of themselves, in some
cases up to 1,000, widely distributed throughout the
genome and the LTRs are able to regulate functional genes
of the host as well as those of the retrovirus. Such LTRs
play a key role in the intra-uterine development of the foe-
tus, shepherding it through the complex recapitulation of
evolution.
Accordingly, HERVs have played a central role in the
evolution of the human species and still have an indispens-
able function in our maturation (Ryan 2009a; Gogvadze
et al. 2009). But there is a price to pay. HERV antigens are
not normally expressed, or are only expressed at low levels,
by the host but in circumstances of inappropriate control
and regulation, expression of HERV genes may initiate or
maintain pathological processes (Larsson and Andersson
1998). Such gene products can be complete or incomplete
viral env or gag proteins or products of recombinational
processes (Laufer et al. 2009). In this context, there is
growing evidence that, by aVecting immune regulation, the
hygiene-related factors mentioned above may facilitate the
abnormal expression of HERV-encoded genetic informa-
tion. The exact mechanisms underlying abnormal HERV
gene expression are poorly understood but in some cases it
is associated with hypomethylation of the relevant viral
genes (Gimenez et al. 2010; Stengel et al. 2010).
There is, however, an ‘Achilles heel’ in the HERV-
mediated induction of pathological changes in cells; namely,
the immune presentation of HERV-encoded epitopes on the
surface of aVected cells, thereby serving as targets for
immune processes that repair or destroy the compromisedJ Cancer Res Clin Oncol (2010) 136:1787–1794 1789
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cell. In principle, genetic expression of HERVs can be con-
trolled by self-speciWc CD8+ T-cells although there may
well be a need for the relevant sub-populations of T-cells to
be expanded and maintained by contacts with environmen-
tal micro-organisms, particularly those encountered early in
life, which by bearing epitopes homologous to the relevant
HERV epitopes induce cross-reactive immune responses.
This raises the possibility that hygiene-related factors may
modify such cross-reactive immunity with, in some cases,
deleterious consequences, but it also raises the prospect of
vaccination strategies to prevent, or immunotherapy to
treat, HERV-related disease processes.
An example of a disease in which abnormal HERV gene
expression appears to play a primary role in the pathologi-
cal processes is melanoma, which has undergone a consid-
erable increase in incidence in the industrialised nations
where, with the exception of lung cancer in women, its inci-
dence is rising more rapidly than any other cancer (Garbe
and Leiter 2009). Indeed, in the light of current understand-
ing, it is a disease that aVords a very good model for eluci-
dating the complex interactions between HERVs,
exogenous infections and the hygiene hypothesis.
Melanoma
In view of occasional reports of spontaneous regressions of
melanoma, suggesting the occurrence of eVective immune
responses, the Febrile Infections and Melanoma (FEBIM)
working group within the Epidemiological Section of the
Melanoma Cooperative Group of the European Organiza-
tion for Research and Treatment of Cancer (EORTC) was
established to conduct epidemiological studies on the
impact of prior infectious diseases and vaccinations on the
risk of melanoma in several European countries and Israel.
The FEBIM group established that a history of serious
but uncommon infections with fever >38.5°C, including
pneumonia, sepsis, pulmonary tuberculosis and Staphylo-
coccus aureus infection, was associated with protection
against melanoma, with the level of protection being
directly related to the number of such infections (Krone
et al. 2005). In addition to naturally occurring infection, it
was demonstrated that vaccination early in life against
smallpox and/or tuberculosis (vaccinia and BCG vaccines)
confers an enduring degree of protection against melanoma.
Adjusted odds ratios (95% conWdence intervals) of risk
were 0.40 (0.18–0.85) for BCG alone, 0.60 (0.36–0.99) for
vaccinia alone and 0.41 (0.25–0.67) for both vaccines. In
addition to this conferred protection, patients developing
melanoma have a signiWcantly better prognosis if they have
received one or both vaccinations (Kölmel et al. 2005).
There is evidence that expression of a human endoge-
nous retrovirus of the HERV-K family is involved in
several stages of carcinogenesis in melanoma, from initiation
of malignant change to development of the clinically evi-
dent tumour (Muster et al. 2003; SeraWno et al. 2009; Singh
et al. 2009). Thus HERV-encoded molecules are suitable
targets for immunotherapy. In this context, an unexpected
Wnding was made: a healthy subject recruited for a trial of a
melanoma vaccine had an expanded population of cyto-
toxic T-cells recognizing an epitope coded for by a HERV-
K (Schiavetti et al. 2002), suggest a mechanism by which
the certain vaccinations and infections might protect
against melanoma. As the HERV-encoded peptide, HERV-
K-MEL, is presented by HLA-molecules on the majority of
human melanomas, the relevant infections and vaccinations
might elicit protection inducing populations of CD8+
T-cells cross-reacting with this target epitope. Amino-acid
sequences with homologies to the HERV-K-MEL peptide
were therefore sought among pathogens and vaccines and
were found in those that conferred protection but not in
those that did not (Krone et al. 2005).
This  Wnding raised the possibility that other vaccines in
routine use might be able to confer protection and could be
identiWed by the presence of epitopes with structurally similar
amino acid sequences. Such a sequence was found in the 17D
yellow fever vaccine and its postulated protective eVect was
conWrmed in a pilot study that also showed that there was a
period of around 10 years between vaccination and observed
protection (Mastrangelo et al. 2009). This time lag suggests
that the induced immune response exerts its protective eVect
at the time of tumour initiation which precedes the clinical
manifestation of the disease by several years or a decade.
HERVs, disease and immune protection
Immunotherapeutic strategies have been investigated in a
mouse model based on a melanoma and a colorectal cancer,
both of which express tumour associated mouse endoge-
nous retrovirus antigens (MERVs) (Kershaw et al. 2001). It
was postulated that immune responses targeting the enve-
lope protein of the MERVs might confer protection.
Accordingly mice were vaccinated either with a MERV
envelope peptide pulsed dendritic cell vaccine or a recom-
binant vaccinia vaccine and challenged with tumour cells
injected into the tail vein. Three weeks later, lung metasta-
ses were counted and showed that vaccination conferred a
high degree of protection by generating immune responses
speciWcally targeting the MERV envelope. This vaccination
strategy was, however, not eVective against tumours that
were already established.
It is highly likely that such protection is mediated by
self-speciWc CD8+ T-cells, the developmental biology and
function of which has been studied in recent years,
although not all their modes of action have been determined1790 J Cancer Res Clin Oncol (2010) 136:1787–1794
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(Jordan et al. 2001; Dhanji and Teh 2003; Mathis and
Benoist 2009). They belong to a distinct lineage and have
developmental requirements distinct from those of conven-
tional CD8+ T-cells, being independent of Tec kinases and
of Ras GRP1 for their development but instead being
dependent on IL-15 and strong interaction with self-anti-
gen. In vitro, they undergo marked proliferation when stim-
ulated with either IL-15 or IL-12 in the absence of TCR
stimulation. Upon activation by IL-15, they produce signiW-
cant amounts of IFN- and can, for example, protect against
infection with listeria via recognition of a self antigen.
While exposure to foreign antigen may not be essential
for the initial induction of these self-speciWc CD8+ memory
T-cells, contact with homologous antigens in an appropriate
co-stimulatory context can increase and maintain relevant
sub-populations of them. During an immune response they
can activate other immune cells to produce a wide range of
cytokines and, in addition, they provide an innate source of
IFN- during an immune response such as against infection.
As discussed above, epidemiological data indicate that
certain infectious diseases and vaccinations against infec-
tious diseases including vaccinia, BCG and yellow fever
vaccinations confer protection against tumour development
at the time of tumour initiation, years or decades before a
clinical manifestation of the malignant disease, either by
cell killing or repair.
A candidate immune mechanism for cell repair is based
on gangliosides of the neo-lacto series, in particular LM1
(Ritter et al. 1986; Nojiri et al. 1988; Schaade et al. 1999,
2000), which are transmitted from leucocytes to the target
cell by direct cell-to-cell contact. LM1 has eVects on cell
growth and diVerentiation and can normalise a malignant
phenotype in various pre-malignant cell-lines by causing
cell cycle arrest within the G0/G1 phase of the cell cycle
(Nojiri et al. 1988; Schaade et al. 1999).
A diVerential display analysis of gene expression (Krone
et al. 2005; Schaade et al. 1999) shows that LM1 mediates
suppression of retroviral RNA; moreover, it also induces a
kelch 1-like protein, one of a family of proteins known to be
involved in transcriptional repression (Wang et al. 2008),
and it induces S-adenosyl-homocysteine-hydrolase, an
enzyme that is essential to the generation of active methyl
groups. These methyl groups are needed for methylation of
DNA which is the most important mechanism by which
cells silence the genetic expression of endogenous retroviral
genes. Further studies on this mechanism would be of great
interest and relevance to carcinogenesis and its suppression.
Unifying principles
The immunoregulatory networks at any given time are the
result of a complex and convoluted history of repeated
encounters with the microbial environment, resulting in
either long term or transient commensalism or acute,
chronic or latent infection. This history, termed the ‘biogra-
phy’ of the immune system (Krone et al. 2009), plays a key
role in health and disease and is crucially aVected by
hygiene-related factors.
Even very small antigenic contacts, so small that they
may not induce measurable immune responses, are able to
‘imprint’ the immune system with patterns of subsequent
reactivity (Menon and Bretscher 1996). In addition,
changes in the timing of sequential infections, due in some
cases to hygiene-related factors, may have major impacts
on the outcome of infection, a phenomenon termed ‘Origi-
nal antigenic sin’ (Editorial 1958). Thus the immune
response to a pathogen often acquired very early in life,
such as the Epstein-Barr virus, may be quite diVerent if the
infection occurs later in life and after infection by patho-
gens bearing cross-reactive epitopes that generate expanded
populations of speciWc memory cells (Krone et al. 2009).
Depending on the biography of the immune system, a
wide range of eVector and regulatory T-cells, and corre-
sponding regulatory networks, with quite diVerent rele-
vance to protection and pathogenesis, will be generated.
Thus various populations of eVector and regulatory cells
may be generated, suppressed or eclipsed and inappropriate
cells that promote pathological processes may be induced
(Krone et al. 2009).
In general, in respect to melanoma, the label of ‘good’ or
‘bad’, beneWcial or detrimental, cannot be applied to the vari-
ous pathogens considered above. It seems that several infect-
ing micro-organisms contribute to the development of
immunoregulatory pathways that protect against melanoma
and the absence of one or more may be compensated by oth-
ers and, collectively, these may be regarded as “old friends”
(Rook 2007). Compared with exogenous viruses, the situation
with HERVs is quite diVerent as they are an integral part of
inherited genetic material, yet their expression and eVect may
be just as hygiene-related as encounters with microorganisms
in the external environment. While on the basis of their central
role in human evolution they are certainly “old friends”, they
can act as “old foes” under some circumstances which are
becoming progressively less avoidable as human populations
increasingly distance themselves from the environmental
micro-organisms encountered by their ancestors.
Are there other examples of HERV-associated 
pathology?
In addition to the example of melanoma discussed above,
HERVs could induce abnormal immune reactions in two
ways. Firstly, abnormally expressed HERV encoded pep-
tides could be recognised as ‘foreign’ and, by inducingJ Cancer Res Clin Oncol (2010) 136:1787–1794 1791
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cross-reactive immune responses including antibody, could
initiate a range of autoimmune diseases. Secondly, a trans-
locating HERV long terminal repeat could promote the
expression of a gene which is usually inactive, yielding a
product which could likewise be recognised as ‘foreign’
(Moyes et al. 2007).
Although, as mentioned above, caution must be
observed in determining whether abnormal HERV expres-
sion is the cause or consequence of a disease process, such
expression has been reported in a number of autoimmune
disorders including rheumatoid arthritis, lupus erythemato-
sus and Sjögren’s syndrome, other connective tissue dis-
eases, various inXammatory neurological diseases (Balada
et al. 2009), and schizophrenia (Huang et al. 2010). Thus,
for example, signiWcantly higher levels of mRNA for a gag
protein of HERV K10 were found in patients with rheuma-
toid arthritis than in those with osteoarthritis and in healthy
controls (Ejtehadi et al. 2006). The expression of members
of three HERV families, HERV-E, -K and -W, has been
detected in 29 of 43 of psoriatic skin lesions but in only
three of 14 lesions of atopic dermatitis and in two of 21 nor-
mal skin samples, but the relevance to pathogenesis has not
been determined (Molès et al. 2005). In schizophrenia,
genes with mRNA sequences homologous to the HERV-W
env gene were detected in plasma from 42 of 118 patients
with recent-onset schizophrenia but in none of 106 healthy
subjects, and this retroviral protein was found to upregulate
several schizophrenia-associated genes (Huang et al. 2010).
In addition, HERV expression has been described in sev-
eral cancers in addition to melanoma, including breast, tera-
toma, seminoma, renal and haematological malignancies
(Schiavetti et al. 2002; Depil et al. 2002; Takahashi et al.
2008; Contreras-Galindo et al. 2008). In most cases, the
expressed HERVs are of the K series, but gene products of
HERV-E are expressed on renal cell carcinomas and may
serve as targets for donor cytotoxic T-cells (Takahashi et al.
2008). In one study, high levels of HERV-K RNA was
detected in sera from patients with either lymphoma or
breast cancer, with whole viral particles being visualised in
sera by electron microscopy, but the levels dropped mark-
edly on treatment (Contreras-Galindo et al. 2008). Despite
these intriguing Wndings, the diverse roles of HERV expres-
sion in cancers, and their causal signiWcance, remains
poorly understood and controversial.
Proof of causal relationships
A similar degree of caution is required in the interpretation
of Wndings of HERV expression in disease processes as in
the determination of the pathogenic role of exogenously
acquired micro-organisms. Thus some form of ‘molecular
Koch’s postulates’ are required. In this context, HERV
expression may represent a normal physiological process
that could well mediate a protective response to disease.
This is particularly the case in the brain in which constitu-
tive and genetically linked expression of several HERVs
has been detected in brain tissue from subjects with and
without neuroinXammatory conditions (Frank et al. 2005).
Koch’s postulates are for several reasons not applicable
to HERV related diseases. Thus, all human cells have
genetic information encoding HERVs and expression of
HERV genes is not detected in all patients with the puta-
tively related disease, since such expression may have initi-
ated the disease process years or decades before the clinical
onset. Moreover, there may be a low level of expression of
the relevant HERVs in persons without the disease. There
are numerous copies of the HERV genes within the human
genome and, as a result of somatic mutations leading to
genetic diversity, certain HERV genes could be expressed
in some healthy individuals.
A critical point in the regulation of HERV activity is
immune control by self-speciWc CD8+ T-cells, and those
with speciWcities for HERV targets are already present
early in life. Immune surveillance may depend on recogni-
tion of a single, or perhaps a very few, target peptides and
may vary from person to person, depending on the proWle
of antigen-presenting HLA-molecules. The eYciency of
immune surveillance may well depend on expansion of the
relevant sub-populations of self-speciWc CD8+ T-cells by
contact with homologous epitopes of exogenous micro-
organisms. Thus a lack of such contact due to hygiene-
related factors enhances the risk of disease. Alternatively,
according to the principle of original antigenic sin, beneWcial
immune responses that are dominant if a micro-organism is
encountered early in life may, if it is encountered later in
life, be eclipsed by responses induced by prior contacts
with antigenically related micro-organisms.
The infectious and immunological background of HERV-
related disease is therefore far more complex than that of the
classical infectious diseases so that none of Koch’s postulates
can be used to conWrm a causal relationship. Instead, collec-
tively, the following factors provide strong indications that a
disease is caused by HERV activity:
1. The human genome codes for the relevant HERV
genes.
2. At least one particular antigen of a speciWc HERV is
detected more frequently in tissues aVected by the dis-
ease under consideration as compared with material
from healthy control persons. In some cases two or
three such antigens such as the env, gag and a peptide
from a related open reading frame would be detected.
3. The incidence of the disease has been signiWcantly
increasing in recent decades in countries with
improved standards of hygiene.1792 J Cancer Res Clin Oncol (2010) 136:1787–1794
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4. Epidemiological studies reveal that a history of certain
infections and vaccinations confer protection against
the given disease and the use of genetic data banks
reveal that protective micro-organisms express epitopes
that could cross-react with the relevant HERV epitopes
but that these are not present in micro-organisms that
are not associated with protection.
5. Vaccines with appropriate cross-reacting epitopes con-
fer protection against the disease if administered at the
time that the initial pathological changes leading to the
disease occur. In the case of melanoma, this would be
around ten years before clinical presentation.
6. A product of a HERV-encoded gene is shown to be
directly involved in pathogenesis of a disease, such as
altered melanin in melanoma (Krone et al. 2005), or
that it upregulates genes associated with expression of
the disease, as in schizophrenia (Huang et al. 2010).
These ‘HERV postulates’ all apply to melanoma, as
described above, and may Wnd a more general application
in the future. Although one of Koch’s postulates, establish-
ing the disease in an experimental animal, is inapplicable,
proof of principle can be obtained by use of analogous ani-
mal models.
Conclusions
A key issue in the emerging discipline of Darwinian medi-
cine, as recently reviewed in detail (Rook 2009), is the
impact of a rapidly changing environment on the acquisi-
tion of a range of micro-organisms that millions of years of
evolution have led the developing immune system to
‘expect’. The other key aspect of this discipline, which can
equally be considered Darwinian, is the impact on health
and disease, and indeed on evolution itself, of the endoge-
nous relics of numerous successive retroviral infections
over huge expanses of time. We postulate that these two
aspects of Darwinian medicine are very closely related,
with  Wne balances between exogenous and endogenous
immune challenges which, if disturbed, can result in dis-
ease.
The study of HERV-induced disease, in contrast to
exogenous viral infections, is in its infancy. Likewise, and
for this reason, no speciWc vaccines against human HERV-
induced disease have been introduced, although vaccines
eliciting tumour protective immune responses against
endogenous retroviral epitopes in the mouse have been
developed (Kershaw et al. 2001). An alternative to develop-
ing novel vaccines is to screen currently available ones for
their ability to generate cross-reacting protective immune
responses to expressed HERV epitopes involved in, or
indicative of, disease processes. Thus, as reviewed above,
epidemiological studies demonstrated that vaccination with
BCG and vaccinia early in life or with yellow fever in adult
life induced signiWcant protection against melanoma.
Although further studies are required, in particular to con-
Wrm the impact of yellow fever vaccination, immunization
strategies of the future may have a two-fold aim—to com-
pensate for the loss of natural encounters with “old friends”
and protection against potential enemies lurking within.
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